Fracture risk remains reduced one year after discontinuation of risedronate.

Fracture risk remains reduced one year after discontinuation of risedronate. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Fracture risk remains reduced one year after discontinuation of risedronate. Abstract Text:

N B Watts,A Chines,W P Olszynski,C D McKeever,M R McClung,X Zhou,A Grauer,N B Watts,A Chines,W P Olszynski,C D McKeever,M R McClung,X Zhou,A Grauer,

One year after discontinuation of three year's treatment with risedronate, BMD decreased at the lumbar spine and femoral neck and bone turnover markers returned to control group levels. Despite these changes, the risk of new morphometric vertebral fractures remained lower in previous risedronate patients compared with previous control patients. INTRODUCTION: Differences in bisphosphonate pharmacology and pharmacokinetics could influence persistence or resolution of the effects once treatment is stopped. We investigated changes in intermediate markers-bone mineral density (BMD) and bone turnover markers (BTM)-and fracture risk after discontinuation of treatment with risedronate. METHODS: Patients who received risedronate 5 mg daily (N = 398) or placebo (N = 361) during the VERT-NA study stopped therapy per protocol after 3 years but continued taking vitamin D (if levels at study entry were low) and calcium and were reassessed one year later. RESULTS: In the year off treatment, spine BMD decreased significantly, but remained higher than baseline (p

Fracture risk remains reduced one year after discontinuation of risedronate. Publishing Authors By Initials

NB Watts,A Chines,WP Olszynski,CD McKeever,MR McClung,X Zhou,A Grauer,NB Watts,A Chines,WP Olszynski,CD McKeever,MR McClung,X Zhou,A Grauer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Fracture risk remains reduced one year after discontinuation of risedronate. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Osteoporosis international : a journal established

VOLUME: 19

Page Numbers: 365-72

Journal Abbreviation:

ISSN: 0937-941X

DAY: 16

MONTH: 10

YEAR: 2007

Fracture risk remains reduced one year after discontinuation of risedronate. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9100105

Fracture risk remains reduced one year after discontinuation of risedronate. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Fracture risk remains reduced one year after discontinuation of risedronate. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Fracture risk remains reduced one year after discontinuation of risedronate.

AFFILIATION: University of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH, 45219, USA, nelson.watts@uc.edu.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Osteoporos Int

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Fracture risk remains reduced one year after discontinuation of risedronate Related Publications

• "Reality" birth: marketing fear to childbearing women.
• (125)I-labeled OP-1 is Locally Retained in a Rabbit Lumbar Fusion Model.
• A rare expression of neural crest disorders: an intrasphenoidal development of the anterior pituitary gland.
• A.E. Grauer: the phantom of public health.
• Acute and chronic reactions to black fly bites; Simulium fly.
• Clinical study of a potent antidepressant: tranylcypromine with trifluoperazine in the aged chronically ill.
• Depression in the aged: theoretical concepts.
• Development of an outpatient geriatric occupational therapy programme in a Montreal hospital, 1960-1966.
• Duodenal ileus (Wilkie's syndrome) arterio-mesenteric ileus.
• Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
• Fracture risk remains reduced one year after discontinuation of risedronate.
• Geriatric patients treated with imipramine: five-year follow-up.
• Heat stability of yeast invertase.
• Hypercalcemia associated with hematologic malignancies.
• Institutions for the aged--therapeutic communities?
• Keloids: etiology, and management by excision and intensive prophylactic radiation.
• Listening to Mothers II as a Catalyst.
• MR findings of exaggerated fluid in facet joints predicts instability.
• Quantifying the effects of degeneration and other patient factors on lumbar segmental range of motion using multivariate analysis.
• Response to Mark Foster's Letter to the Editor.
• Silicates and bone fusion.
• Sterility of C-arm Fluoroscopy During Spinal Surgery.
• The radiation exposure associated with cervical and lumbar spine radiographs.
• The use of propyl thiouracil and of radioactive iodine.
• The utility of dynamic flexion-extension radiographs in the initial evaluation of the degenerative lumbar spine.
• Therapeutic value of arts and crafts in a geriatric hospital.
• Transhepatic portal venous power-pulse spray rheolytic thrombectomy for acute portal vein thrombosis after CT-guided pancreas biopsy.
• [Not Available.]
• [Not Available.]
• [Optimal labor induction using PG F2alpha in diabetes mellitus]